Selecta Biosciences Imm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid

United statesUniversity of texas southwestern medical centerRoy fleischmannSelecta biosciences immHerbert sb barafBiovitrum sobiEuropean congressGeorge washington universityMetroplex clinical research centerDrug administrationSelecta biosciencesSwedish orphan biovitrumTexas southwestern medical centerImmune toleranceOint inflammationBody mass index bmi